Skip to main content
SpringerLink
Log in

Impact of glycemic control over cardiac autonomic neuropathy

  • Research article
  • Published:
Journal of Diabetes & Metabolic Disorders Aims and scope Submit manuscript

Abstract

Purpose

Cardiovascular autonomic neuropathy (CAN) is one of the most common and serious complications associated with diabetes and is defined as the impairment of the autonomic control of the cardiovascular system, whose prevalence in Indian population has been reported to be > 50%. The risk factors associated with CAN include hyperglycemia, duration of diabetes, hypertension, dyslipidemia, and obesity. This study was conducted to examine the association of CAN with its determinants among diabetics.

Methods

Socio-demographic characteristics were noted alongwith performance of biochemical analyses of blood samples according to standard hospital pathology laboratory protocols. Clinical assessment of CAN comprised a of 5 indexes, including 3 heart rate variability parameters (resting tachycardia, Qtc interval > 440 msec, exercise intolerance) and 2 blood pressure parameters (orthostatic hypotension, abnormal hand gripping test).

Results

The odds of CAN increased with poor glycemic control (FBS ≥ 126 mg/dL (OR = 1.17 (1.02–10.68); 2 hr PPBS ≥ 200 mg/dL (OR 1.63 (1.26–8.82) and HbA1c ≥ 6.5% (OR = 10.68 (1.54–208.02). Significant difference was also found in relation to duration of diabetes, weight and body mass index of the participants with various grades of CAN.

Conclusions

CAN is associated strongly with poor glycemic control. Obesity seems to be involved in the impairments of the cardiac autonomic function and this factor must therefore be taken into account in future studies when interpreting the results. Body mass control and glycemic control could provide an important approach to reducing CAN.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data availability

Can be provided upon request.

References

  1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. https://doi.org/10.1016/j.diabres.2017.03.024.

    Article  CAS  Google Scholar 

  2. Federation ID. IDF Diabetes Atlas 2019 Update. 2019. Available from: http://www.idf.org/diabetesatlas/5e/Update2019. Accessed 20 July 2020.

  3. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035–8.

    Article  CAS  Google Scholar 

  4. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–46.

    Article  CAS  Google Scholar 

  5. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.

    Article  CAS  Google Scholar 

  6. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–93.

    Article  Google Scholar 

  7. Intensive blood-glucose. control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–53.

    Article  Google Scholar 

  8. Tight blood pressure control. and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703–13.

    Article  Google Scholar 

  9. Maser RE, Lenhard JM, DeCherney SG. Cardiovascular autonomic neuropathy: The clinical significance of its determination. Endocrinologist. 2000;10:27–33.

    Article  Google Scholar 

  10. Maser RE, Pfeifer MA, Dorman JS, Kuller LH, Becker DJ, Orchard TJ. Diabetic autonomic neuropathy and cardiovascular risk. Pittsburgh epidemiology of diabetes complications study III. Arch Intern Med. 1990;150:1218–22.

    Article  CAS  Google Scholar 

  11. Dimitropoulos G, Tahrani AA, Stevens MJ. Cardiac autonomic neuropathy in patients with diabetes mellitus. World J Diabetes. 2014;5(1):17–39.

    Article  Google Scholar 

  12. Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4(1):4–18.

    Article  CAS  Google Scholar 

  13. Sukla P, Shrivastava SR, Shrivastava PS, Rao NL. Assessment of the cardiac autonomic neuropathy among the known diabetics and age-matched controls using noninvasive cardiovascular reflex tests in a South-Indian population: A case-control study. Avicenna J Med. 2016;6(3):81–5.

    Article  Google Scholar 

  14. Spallone V, Ziegler D, Freeman R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639–53. Toronto Consensus Panel on Diabetic Neuropathy.

  15. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diab Care. 2010;33(10):2285–93.

    Article  Google Scholar 

  16. Balcıoğlu AS, Müderrisoğlu H. Diabetes and cardiac autonomic neuropathy: Clinical manifestations, cardiovascular consequences, diagnosis and treatment. Diabetes Care. 2010;33(2):434–41.

    Article  Google Scholar 

  17. Ewing DJ, Clark BF. Diagnosis and management of diabetic autonomic neuropathy. Br Med J. 1982;285:916–8.

    Article  CAS  Google Scholar 

  18. Aggarwal S, Tonpay PS, Trikha S, Bansal A. Prevalence of autonomic neuropathy in diabetes mellitus. Curr Neurobiol. 2011;2(2):101–5.

    Google Scholar 

  19. Okin PM, Lauer MS, Kligfield P. Chronotropic response to exercise. Improved performance of ST segment depression criteria after adjustment for heart rate reserve. Circulation. 1996;94:3226 – 31.

    Article  CAS  Google Scholar 

  20. Valensi P, Paries J, Attali JR. Cardiac autonomic neuropathy in diabetic patients: influence of diabetes duration, obesity, and microangiopathic complications–the French multicenter study. Metab Clin Exp. 2003;52(7):815–20.

    Article  CAS  Google Scholar 

  21. Nijhawan S, Mathur A, Singh V, Bhandari VM. Autonomic and peripheral neuropathy in insulin dependent diabetics. J Assoc Phys India. 1993;41:565–6.

    CAS  Google Scholar 

  22. Krolewski AS, Berzilay J, Warram JH, et al. Risk of early-onsetproliferative retinopathy in IDDM is closerly related to cardiovascularautonomic neuropathy. Diabetes. 1992;41:430–7.

    Article  CAS  Google Scholar 

  23. Bergstrom B, Lilja B, Osterlin S, Sundkvist G. Autonomic neuropathy innon-insulin-dependent (type II) diabetes mellitus: Possible influence ofobesity. J Intern Med. 1990;227:57–63.

    Article  CAS  Google Scholar 

  24. Straub RH, Thum M, Hollerbach C, Palitzsch KD, Schölmerich J. Impact of obesity on neuropathic late complications in NIDDM. Diabetes Care. 1994;17(11):1290–4.

    Article  CAS  Google Scholar 

  25. McDaid EA, Monaghan B, Parker AI, Hayes JR, Allen JA. Peripheral autonomic impairment in patients newly diagnosed with type II diabetes. Diabetes Care. 1994;17(12):1422–7.

    Article  CAS  Google Scholar 

  26. Witte DR, Tesfaye S, Chaturvedi N, Eaton EM, Kempler P, Fuller JH. Risk factors for cardiac autonomic neuropathy in type 1 diabetes mellitus. Diabetologia. 2005;48(1):164–71.

    Article  CAS  Google Scholar 

  27. Ramachandran A, Snehalatha C, Kapur A, Vijay V, Mohan V, Das AK, Rao PV, Yajnik CS, Kumar KMP, Nair JD. High prevalence of diabetes and impaired glucose tolerance in India: National urban diabetes survey. Diabetologia. 2001;44(9):1094–101.

    Article  CAS  Google Scholar 

  28. Brownlee M. Diabetic complications: pathobiology of hyperglycemic damage and potential impact on treatment. In: Thornalley PJ, Kempler P, editors. Complications of diabetes mellitus: pathophysiology and pathogenetically-based treatment options. Stuttgart: Georg Thieme Verlag KG; 2009. pp. 1–8.

    Google Scholar 

  29. Calles-Escandon J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care. 2010;33:721–7. https://doi.org/10.2337/dc09-1471.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the action to control cardiovascular risk in diabetes (ACCORD) trial. Diabetes Care. 2010;33:1578–84. https://doi.org/10.2337/dc10-0125.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Medicine, AIIMS Bhubaneswar, Bhubaneswar, Odisha, 751019, India

    Meghanad Meher

  2. Department of General Medicine, SCB Medical College & Hospital, Cuttack, Odisha, 753007, India

    Jayanta Kumar Panda

Authors
  1. Meghanad Meher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jayanta Kumar Panda
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Dr. Meghanad Meher and Dr. Jayanta Kumar Panda. The first draft of the manuscript was written by Dr. Meghanad Meher and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Meghanad Meher.

Ethics declarations

Conflict of interest

Not Applicable. 

Ethics approval

The study was approved for conduct by the Institute Ethics Committee, SCB Medical College and Hospital, Cuttack (548/16.09.2017). 

Consent to participate

A written informed consent was taken from all the participants explaining the study details. 

Consent for publication

Not Applicable. 

Code availability

Not Applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Meher, M., Panda, J.K. Impact of glycemic control over cardiac autonomic neuropathy. J Diabetes Metab Disord 19, 1339–1344 (2020). https://doi.org/10.1007/s40200-020-00653-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40200-020-00653-7

Keywords

Search

Navigation